Related Experiment Video

Updated: May 31, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Anti-cancer peptides from ras-p21 and p53 proteins

Matthew R Pincus1, Maly Fenelus, Ehsan Sarafraz-Yazdi

  • 1Department of Pathology & Laboratory Medicine, New York Harbor VA Medical Center, Brooklyn, NY 11209, USA. matthew.pincus2@med.va.gov

Current Pharmaceutical Design
|July 7, 2011
PubMed

Insights

Novel peptides designed using molecular modeling target cancer cells by inducing reversion or necrosis. These ras and p53-derived peptides show promise as anti-tumor agents with no observed side effects on normal cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Design

Background:

  • Oncogenic proteins like ras-p21 and p53 play critical roles in cancer development.
  • Targeting cancer-specific pathways is crucial for effective anti-tumor therapies.
  • Developing agents that selectively eliminate cancer cells without harming normal cells remains a significant challenge.

Purpose of the Study:

  • To design and evaluate novel peptides derived from ras-p21 and p53 proteins as potential anti-cancer agents.
  • To investigate the mechanism of action of these peptides in inducing tumor cell reversion or necrosis.
  • To assess the selectivity of these peptides towards cancer cells versus normal cells.

Main Methods:

  • Computer-based molecular modeling was used to identify key domains in ras-p21 and p53 proteins.
  • Peptides corresponding to these domains were synthesized, including ras peptides (PNC-7, PNC-2) and p53-derived peptides (PNC-27, PNC-28).
  • Peptides were conjugated to a membrane-penetrating peptide (membrane residency peptide or MRP) for cellular delivery. In vitro and in vivo studies were conducted to assess anti-tumor efficacy and selectivity.

Main Results:

  • Ras peptides (PNC-7, PNC-2) blocked oncogenic ras-p21-induced oocyte maturation, indicating pathway specificity.
  • MRP-conjugated ras peptides induced phenotypic reversion or necrosis in ras-transformed cell lines without affecting normal cells.
  • MRP-conjugated p53 peptides (PNC-27, PNC-28) formed pores in cancer cell membranes (due to HDM-2 expression) but not normal cells, eradicating tumors in mice with no side effects.

Conclusions:

  • Designed ras and p53 peptides demonstrate selective anti-tumor activity through distinct mechanisms.
  • These peptides offer a promising new strategy for cancer therapy, targeting cancer cells specifically.
  • Further development of these peptides as anti-cancer agents is warranted based on their efficacy and safety profile.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...